UCB not for sale; Shire strikes Adderall XR deal with Sandoz;

@FiercePharma: Irish plant shutdown puts another Merck site on the block. Story from FiercePharmaManufacturing | Follow @FiercePharma

@EricPFierce: Analysts predicted Forest would do something to cut costs. Here it is. Release | Follow @EricPFierce

@CarlyHFierce: This disease database digitization project is named for Tycho Brahe, Prague's imperial astronomer in the late 1500s. Story | Follow @CarlyHFierce

> Belgian drugmaker UCB's largest shareholder says the company is not for sale. Story

> Shire ($SHPG) has reached an agreement with Sandoz for the generic arm of Novartis ($NVS) to sell an exclusive generic version of ADHD drug Adderall XR in the U.S. beginning July 1, 2016. Story

> The Indian government has tabled its move to limit direct foreign investment in pharma companies amid building opposition from the Finance Ministry and the Planning Commission. Story

> President Obama has signed the Drug Quality and Security Act, the new law that gives the FDA expanded responsibilities over compounding pharmacies and kicks off the move toward a national track-and-trace system in the U.S. Story

Medical Device News

@FierceMedDev: Report: Insurers could gain up to $1B in J&J hip settlement deal. Item | Follow @FierceMedDev

@MarkHFierce: LabCorp has become the latest to roll out new BRCA tests - wondering when Myriad will sue them, too. Release | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Study: Natural nanomaterials could support biodegradable drug delivery. Story | Follow @MichaelGFierce

@GalenMoore: Infectious-disease biotech Visterra has raised $8.1M and licensed dengue-fever IP from its co-founder's lab at MIT. More | Follow @GalenMoore

> HeartWare bags CircuLite for up to $350M with eye on bigger market share. Article

> University of Toronto molecular Dx spinout pulls in $18.8M Series B. Report

> NEJM study ties Thoratec's HeartMate pump to blood clots. More

> Ardian vet, early Google employee post $3.8M for stealthy med tech startup. Story

> Abbott recalls glucose test strips over risk with older-model meters. Piece

Biotech News

@FierceBiotech: PharmAthene scraps Theraclone merger after feds nix funding. More | Follow @FierceBiotech

@JohnCFierce: Forest Labs takes aim at R&D in $500M cost-cutting blitz. News | Follow @JohnCFierce

@DamianFierce: Aptuit poached a former $ICLR VP to serve as next CEO. Story | Follow @DamianFierce

@EmilyMFierce: Novartis announced on Thanksgiving that its scientists have discovered a new malaria target. Release | Follow @EmilyMFierce

> Visterra hires AMAG, Concert vets, licenses dengue antibody from MIT. Story

> FDA delays Biogen's application on hemophilia B therapy. Item

Biotech IT News

> Computational biology startup joins Merck KGaA's incubator. More

> Digitization work turns 125 years of disease reports into Big Data goldmine. News

> Pfizer: 'Bring your own device' is coming to clinical trials. Story

> Academics dig into EMRs to discover genetic causes of disease. Article

> Report suggests biopharma wise to outsource cybersecurity. Piece

> Sony files patent for wearable computing 'SmartWig'. Item

CRO News

> Analyst: Pharma R&D cuts won't hamper big CROs. Story

> Almac banks $9M in diagnostics deal with Genomic Health. More

> CRO SillaJen eyes $150M deal for ex-sponsor. News

> Evoke picks SynteractHCR to helm PhIII for diabetes drug. Piece

> Aptuit snags ex-Icon exec to serve as CEO. Article

> Parexel: Strategic partnerships are the future. Item

And Finally... Studies will soon start to see if Pfizer's ($PFE) Chantix, a drug to help smokers quit, might also work for problem drinkers. Story

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.